Further to its press release of March 20, 2020, Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company) announced that, in response to the evolving dynamics related to the COVID-19 pandemic, it has decided to delay the release of its fourth quarter and full year 2019 financial results, originally scheduled for March 26, 2020, until after market close on Thursday, April 2, 2020.
In deciding to postpone its annual filings by one week, Kane Biotech is relying upon the Canadian Securities Administrators’ blanket relief, which, in light of recent COVID-19 developments and their impact on market participants, provides a 45-day extension for periodic filings normally required to be made by issuers, investment funds, registrants, certain regulated entities and designated rating organizations on or before June 1, 2020.
Kane Biotech management will host a conference call at 4:30 p.m. ET on April 2, 2020 to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2019 Results Conference Call Details: | |
Date: | Thursday, April 2, 2020 |
Time: | 4:30 p.m. ET |
Live Call: | 1-877-268-9044 (Canada and the United States) |
1-706-679-2995 (International) | |
Replay: | 1-404-537-3406 |
Conference ID: | 8118809 |
The call will also be broadcast live and archived on the Company’s website at www.kanebiotech.com under “News/Events” in the Investors section.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (57 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNBTM, DispersinB®, Aledex®, bluestemTM, silkstemTM, coactiv+TM and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE”.
For more information, please visit www.kanebiotech.com, or contact:
Marc Edwards | |
Chief Executive Officer | |
Kane Biotech Inc. | |
+1 (514) 910-6991 | medwards@kanebiotech.com |
Ray Dupuis | |
Chief Financial Officer | |
Kane Biotech Inc. | |
+1 (204) 298-2200 | rdupuis@kanebiotech.com |
Stephen Kilmer | |
Investor Relations | |
+1 (646) 274-3580 | skilmer@kanebiotech.com |